Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03178201 · ClinicalTrials.gov registry record · Phase 2
TGR1202 in Relapsed and Refractory Follicular Lymphoma
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03178201: Clinical Trial Phase 2 study, sponsored by Columbia University.
NCT03178201 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03178201, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective is to determine the overall response rate (ORR) of TGR-1202 in R/R FL. Secondary Objectives * Determine the genetic and other novel biological markers that may be predictive of response or resistance to TGR-1202 in patients with relapsed or refractory FL. * Describe the Progression Free Survival (PFS), Duration of Response (DoR) after treatment with TGR-1202. * Describe the number of dose delays and dose reductions and other safety profile.
Primary Outcome
The sum of patients with partial responses and complete responses.
Interventions
- DRUG TGR-1202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-08-20 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 2 |
Why NCT03178201 stopped before completion
NCT03178201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which TGR-1202 is the first listed.
NCT03178201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03178201 about?
NCT03178201 is a clinical study titled "TGR1202 in Relapsed and Refractory Follicular Lymphoma". The primary objective is to determine the overall response rate (ORR) of TGR-1202 in R/R FL. Secondary Objectives * Determine the genetic and other novel biological markers that may be predictive of response or resistance to TGR-1202 in patients with relapsed or refractory FL. * Describe the Progr...
What is the current status of trial NCT03178201?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-08-20. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03178201?
The interventions under investigation include: TGR-1202 (DRUG).
Who is sponsoring clinical trial NCT03178201?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03178201's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI